Additionally, destruxin A5, a compound inhibiting PDGF‐BB/PDGFR‐β signaling, alleviated liver fibrosis in BDL‐treated mice, reducing α‐SMA expression and collagen deposition in preclinical studies, further supporting the therapeutic promise of PDGFR‐β blockade [29]. The gene discussed is ACTA1; the disease is Hepatic fibrosis.